Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars

Fineline Cube Feb 27, 2026
Company Deals Drug

Jumpcan Pharma Secures China Rights to Thederma’s TAP-1503 – First AhR Modulator for Atopic Dermatitis

Fineline Cube Feb 27, 2026
Company Deals

WuXi XDC Licenses WuXiTecan-2 Technology to Earendil Labs – $885M Deal Powers AI‑Driven ADC Development

Fineline Cube Feb 27, 2026
Company Deals

SteinCares Partners with Shilpa Biologicals on Latin America Biosimilar Deal – Regional Commercialization Agreement

Fineline Cube Feb 26, 2026
Company Deals

Danaher to Acquire Masimo for $9.9B – Expands Diagnostics Platform with Pulse Oximetry Leader

Fineline Cube Feb 26, 2026
Policy / Regulatory

NMPA Approves 76 Innovative Medical Devices in 2025 – 17% YoY Growth Driven by AI and Priority Review Surge

Fineline Cube Feb 26, 2026
Company Drug

Gan & Lee’s Insulin Biosimilars Win CHMP Positive Opinion – Bysumlog and Dazparda Near EU Market Entry

Fineline Cube Feb 27, 2026
Company Drug

Kanghong Pharma’s Orexin Antagonist KHN707 Cleared for Insomnia Trials – First-in-Class Sleep Disorder Candidate

Fineline Cube Feb 27, 2026
Company

WuXi Bio Reports 2023 Revenue Growth Amid COVID-19 Business Loss and Geopolitical Tensions

Fineline Cube Mar 27, 2024

WuXi Bio (HKG: 2269), a leading Contract Research, Development, and Manufacturing Organization (CRDMO) based in...

Company Drug

Innovent Biologics Initiates Phase III Neoshot Study for MSI-H/dMMR Colon Cancer Treatment

Fineline Cube Mar 27, 2024

Innovent Biologics, Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced the...

Company Drug

Alexion’s Ultomiris Secures FDA Approval for Anti-AQP4 Positive NMOSD Treatment

Fineline Cube Mar 27, 2024

AstraZeneca’s (AZ; NASDAQ: AZN) rare disease unit, Alexion, has registered its biologic Ultomiris (ravulizumab) with...

Policy / Regulatory

NMPA Mandates Electronic Permits for Anesthetic Drugs and Psychotropic Substances

Fineline Cube Mar 27, 2024

The National Medical Products Administration (NMPA) has issued a new notification aimed at enhancing the...

Company

Shanghai Fosun Pharma Reports 2023 Revenues, Highlights Innovation and R&D Progress

Fineline Cube Mar 27, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...

Company Deals

AbbVie Acquires Landos Biopharma to Boost Autoimmune Disease Pipeline

Fineline Cube Mar 27, 2024

AbbVie (NYSE: ABBV) has announced its acquisition of Landos Biopharma (NASDAQ: LABP), a biopharmaceutical company...

Policy / Regulatory

National Drug Sampling Inspection Report Reveals High Compliance Rates in 2023

Fineline Cube Mar 27, 2024

The National Institute for Food and Drug Control (NIFDC) has released its “National Drug Sampling...

Company Drug

MSD’s Winrevair Approved by FDA as First Activin Signaling Inhibitor for Pulmonary Arterial Hypertension

Fineline Cube Mar 27, 2024

The US Food and Drug Administration (FDA) has granted Merck, Sharp & Dohme (MSD; NYSE:...

Policy / Regulatory

China’s National Adverse Drug Reaction Report for 2023 Highlights Stability in Reporting Trends

Fineline Cube Mar 27, 2024

The National Center for ADR Monitoring has released its “National Adverse Drug Reaction Monitoring Annual...

Company

Lee’s Pharmaceutical Holdings Ltd Reports 2023 Financials with Focus Shift to Patented and Generic Drugs

Fineline Cube Mar 27, 2024

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), a leading pharmaceutical company based in China, has released...

Company

Hansoh Pharmaceutical Group Reports 7.7% YOY Revenue Growth and Expands R&D Spending

Fineline Cube Mar 27, 2024

Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has announced its financial results for 2023, reporting...

Company Deals

Shanghai Pharmaceuticals, SHC, and CEMCS CAS Renew Partnership to Incubate Pharmaceutical Innovations

Fineline Cube Mar 27, 2024

Shanghai Pharmaceuticals Holding Co., Ltd. (SPH, SHA: 601607; HKG: 2607), a leading pharmaceutical company in...

Company Policy / Regulatory

Kobayashi Pharmaceutical Recalls Red Yeast Rice Pills in China Amid Health Concerns

Fineline Cube Mar 26, 2024

Japan-based Kobayashi Pharmaceutical has reportedly initiated a product recall in the Chinese market for its...

Company Policy / Regulatory

Surprise Resignation: Congressman Gallagher Steps Down as Biosecure Act Faces Uncertainty

Fineline Cube Mar 26, 2024

U.S. Congressman Mike Gallagher, the key proponent behind the recently introduced Biosecure Act aimed at...

Company Deals

Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Deal Amid Biotech Pressures

Fineline Cube Mar 26, 2024

U.S.-based biotech Nuvation Bio Inc. (NYSE: NUVB) has announced a definitive agreement to acquire China-based...

Company Drug

FDA Grants Full Approval to AbbVie’s Elahere for Advanced Ovarian Cancer Treatment

Fineline Cube Mar 26, 2024

This week, the U.S. Food and Drug Administration (FDA) granted full approval to AbbVie’s (NYSE:...

Company Deals Hospital

Fosun Health and Adventist Medical Center Partner to Enhance GBA Medical Services

Fineline Cube Mar 26, 2024

China-based Fosun Health Consumption Industry Group has entered into a strategic partnership with Hong Kong’s...

Company Deals Drug

Biocytogen and ABL Bio Forge Partnership to Advance Bispecific ADC Development

Fineline Cube Mar 26, 2024

China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) has entered into a partnership with South...

Company Deals

HitGen Secures Strategic Partnerships to Enhance Drug Discovery for Startups

Fineline Cube Mar 26, 2024

China-based HitGen Inc. (SHA: 688222) has announced strategic partnerships with LabCentral, a prominent life science...

Company Drug

CanSino Biologics Launches Phase III Study for Menhycia Vaccine in Indonesia

Fineline Cube Mar 26, 2024

China-based CanSino Biologics (HKG: 6185) has announced the launch of a Phase III clinical study...

Posts pagination

1 … 345 346 347 … 627

Recent updates

  • Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars
  • Zai Lab Reports $457M Full‑Year Revenue – 16% Growth Driven by Xacduro and Nuzyra Expansion
  • Gan & Lee’s Insulin Biosimilars Win CHMP Positive Opinion – Bysumlog and Dazparda Near EU Market Entry
  • Kanghong Pharma’s Orexin Antagonist KHN707 Cleared for Insomnia Trials – First-in-Class Sleep Disorder Candidate
  • Akeso’s Manfidokimab NDA Accepted by NMPA – Anti-IL-4Rα mAb Targets Moderate-to-Severe Atopic Dermatitis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Tonghua Dongbao Partners with Huisheng Biopharma – Secures China Rights to First Domestic Insulin Degludec Biosimilars

Company

Zai Lab Reports $457M Full‑Year Revenue – 16% Growth Driven by Xacduro and Nuzyra Expansion

Company Drug

Gan & Lee’s Insulin Biosimilars Win CHMP Positive Opinion – Bysumlog and Dazparda Near EU Market Entry

Company Drug

Kanghong Pharma’s Orexin Antagonist KHN707 Cleared for Insomnia Trials – First-in-Class Sleep Disorder Candidate

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.